Literature DB >> 2424978

Properties of a panel of monoclonal antibodies which react with the human T cell antigen receptor on the leukemic line HPB-ALL and a subset of normal peripheral blood T lymphocytes.

A W Boylston, J Borst, H Yssel, D Blanchard, H Spits, J E de Vries.   

Abstract

Five Mab raised against the T cell antigen receptor of the human T cell line HPB-ALL which react with a subpopulation of normal peripheral blood T cells are described. Three Mab, 3D6, 1C1, and 1C2, react with 3 to 5% of normal PBL and stimulate proliferation of the cells with which they react. An increase in the number of cells which react with all five Mab occurs. Two Mab, 2D4 and 65, react with subsets of the cells which bind 1C1, 1C2, and 3D6 and divide the family into four subgroups, 2D4+ 65+, 2D4+ 65-, 2D4- 65+, and 2D4- 65-. Functional T cell clones in all four subfamilies have been observed. Cytolytic function can be correlated with the TcR phenotype expressed because all of the Mab which react with a particular clone inhibit its ability to lyse a specific target. The epitopes recognized by the panel are closely related because all five block each other's binding to HPB-ALL. In addition, the determinants recognized by 3D6, 1C1, and 1C2 on normal lymphocytes are probably very closely related because all clones examined react with all three Mab.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424978

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  A persistent T cell expansion in the peripheral blood of a normal adult male: a new clinical entity?

Authors:  J Grunewald; M Jeddi-Tehrani; H Dersimonian; R Andersson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  T cell receptor V beta variable gene family expression in human peripheral blood lymphocytes at the mRNA and membrane protein level.

Authors:  H Z Hu; R A de Weger; K Bosboom-Kalsbeek; M G Tilanus; J Rozing; H J Schuurman
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Selective manipulation of the human T-cell receptor repertoire expressed by thymocytes in organ culture.

Authors:  M Merkenschlager; A G Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

4.  Diversity of T-cell antigen receptor variable genes used by mycosis fungoides cells.

Authors:  D W Bahler; G Berry; J Oksenberg; R A Warnke; R Levy
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

5.  T-cell receptor V beta 5 usage defines reactivity to a human T-cell receptor monoclonal antibody.

Authors:  M Lipoldova; A W Boylston; H Yssel; M J Owen
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

6.  Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis.

Authors:  F M Brennan; S Allard; M Londei; C Savill; A Boylston; S Carrel; R N Maini; M Feldmann
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

7.  T-cell receptor beta-chain gene usage in the T-cell recognition of Mycobacterium leprae antigens in one tuberculoid leprosy patient.

Authors:  W C van Schooten; J L Ko; N van der Stoep; J B Haanen; L Pickering; R R de Vries; P van den Elsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

8.  WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis.

Authors:  B S Klein; P M Sondel; J M Jones
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Human T cells expressing V beta 8 do not predominantly recognize DR2 alloantigen.

Authors:  S E Christmas; R Brew; I Crosby; I E Gecim; R A Sells
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

10.  Staphylococcal exotoxins deliver activation signals to human T-cell clones via major histocompatibility complex class II molecules.

Authors:  F Spertini; H Spits; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.